Products for Research Use Only

Leelamine

CAT: 0804-HY-W005629-01Size: 500 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-W005629-01Size:500 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Leelamine is an orally active pyruvate dehydrogenase kinase (PDK) inhibitor with an IC50 value of 9.5 μM, showing a blood glucose lowering effect in the diabetic mouse. Leelamine is also a weak agonist of cannabinoid receptors CB1 and CB2. Leelamine decreases mitotic activity, prostate-specific antigen expression and induces Apoptosis to cell death in cancer cells[1][2][3].
CAS Number
1446-61-3
UNSPSC
12352005
Hazard Statement
H315, H319, H335
Target
Cannabinoid Receptor; PDK-1
Type
Reference compound
Related Pathways
GPCR/G Protein; Neuronal Signaling; PI3K/Akt/mTOR
Applications
Cancer-Kinase/protease
Field of Research
Cancer; Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/leelamine.html
Concentration
10mM
Purity
98.36
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
NC[C@]1(C)CCC[C@]2(C)C3=C(CC[C@@]12[H])C=C(C(C)C)C=C3
Molecular Formula
C20H31N
Molecular Weight
285.48
Precautions
H315, H319, H335
References & Citations
[1]Merarchi M, et, al. A Brief Overview of the Antitumoral Actions of Leelamine. Biomedicines. 2019 Jul 19;7 (3) :53. |[2]Kuzu OF, Gowda R, Sharma A, Robertson GP. Leelamine mediates cancer cell death through inhibition of intracellular cholesterol transport. Mol Cancer Ther. 2014;13 (7) :1690-1703. |[3]Aicher TD, et al. Triterpene and diterpene inhibitors of pyruvate dehydrogenase kinase (PDK) . Bioorg Med Chem Lett. 1999 Aug 2;9 (15) :2223-8.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CB1; CB2